Potent indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50
values are 19 and 67 nM in enzymatic activity and HeLa cell assays, respectively). Decreases kynurenine levels in plasma and reduces tumor growth in vivo
. Cell membrane permeable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Cancer immunotherapy: selected targets and small-molecule modulators.
Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.
Yue et al.
Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway.
Dounay et al.